MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Inclusion Criteria: 1. Ability to understand and provide informed consent. 2. Willingness and ability to comply with scheduled study visits and procedures. 3. Adult men or women age ≥ 18 years. 4. ECOG performance status of 0 or 1. 5. Part 1A monotherapy: Advanced/metastatic NSCLC, cSCC, Merkel cell, melanoma, TNBC, pancreatic cancer, or head and neck cancer. 6. Parts 1B and 1C combination: Advanced/metastatic NSCLC which has progressed following front-line anti-PD-1/PD-L1 with or without concurrent chemotherapy. 7. Per each tumor type shown below, the specific initial standard of care therapies after which the subjects with specific histologies must have progressed have been included. Subjects will have been treated with at least one or more than one line of therapy prior to enrollment in the study. 1. Non-small cell lung cancer (NSCLC) Part 1A monotherapy * Must have progressed on standard therapy, including platinum-based chemotherapy and checkpoint inhibitor therapy (combined or sequential). * Patients with tumors that have known actionable molecular alteration such in EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS must have progressed on standard directed molecular therapy, and platinum-based chemotherapy. Part 1B MEM-288 plus nivolumab combination * Must have first progression more than (\>) 84 days following initiation (cycle 1 day 1) of their most recent anti-PD-1 or PD-L1 checkpoint inhibitor therapy with or without concurrent chemotherapy Part 1C MEM-288 plus docetaxel combination must have either: * first progression with anti-PD-1 or PD-L1 checkpoint inhibitor therapy with or without concurrent chemotherapy, or * progressed following initial first line anti-PD-1 or PD-L1 monotherapy followed by 2nd line platinum chemotherapy (with or without continuation of their first line anti-PD-1 or PD-L1 therapy). 2. Cutaneous squamous-cell carcinoma (cSCC) * Must have progressed on standard therapy, including platinum-based chemotherapy and/or checkpoint inhibitor therapy. 3. Merkel cell Carcinoma * Must have progressed on standard checkpoint inhibitor therapy. 4. Melanoma * Subjects must have received a BRAF inhibitor as monotherapy or in combination with other targeted agents for BRAF V600E mutant melanoma. * Subjects must have received an anti-PD-1/ PD-L1inhibitor as monotherapy or combination with anti-CTLA-4 inhibitor or other therapies. 5. Pancreatic cancer * Progression after systemic chemotherapy which included either gemcitabine or Fluorouracil (5-FU)-based regimen (including capecitabine). 6. Triple negative breast cancer (TNBC) * Prior treatment (for advanced, metastatic or (neo)adjuvant) must have included a taxane and/or anthracycline-based therapy. 7. Head and Neck Cancer * Prior treatment requirement in the metastatic or unresectable locally advanced setting include: * Subjects must have received a platinum containing chemotherapy regimen for treatment of primary tumor in locally advanced, or metastatic settings * Subjects must have received an anti-PD-1/ PD-L1 as monotherapy or in combination with chemotherapy. 8. Progressed following therapy with at least one PD-1 or PD-L1 checkpoint inhibitor (regardless of PD-L1 expression status), except for patients with pancreatic cancer. a) Prior progression on a PD-1 or PD-L1 checkpoint inhibitor should be unequivocal; progression that occurs within the first 8 weeks of treatment on these agents should be confirmed with a second CT at least 4 weeks apart (to exclude pseudo-progression). 9. Patients with activating EGFR mutation or ALK rearrangement which is expected to be responsive to available tyrosine kinase inhibitor therapy, must have been previously treated with an applicable tyrosine kinase inhibitor. 10. Tumor lesion which is deemed feasible for biopsy and injection under CT or ultrasound guidance (based on size, location, and visibility) by an interventional radiologist, and patient willing and able to provide tissue from biopsy of this lesion. Injected tumor should be \> 1 cm3 in volume and should not encase or be inseparable from vital structures such as major nerves or blood vessels. a) For Part 1 monotherapy patients treated at the first dose level, the tumor for injection must be an accessible cutaneous, subcutaneous, or superficial lymph node lesion that is palpable. 11. Measurable disease, as defined per RECIST version 1.1. 12. Prior history of brain metastases are eligible, provided: 1. Brain metastases have been treated 2. Asymptomatic from the brain metastases 3. Corticosteroids prescribed for the management of brain metastases have been discontinued at least 7 days before registration to study 4. Brain metastases are stable on pre-registration imaging 5. No evidence of leptomeningeal disease 13. Life expectancy \> 3 months. 14. Adequate organ and marrow function as defined below: 1. Absolute neutrophil count (ANC) ≥1.5 x 10\^9/L 2. Hemoglobin ≥90 g/L (or ≥9 g/dL) 3. Platelets ≥100 x 10\^9/L 4. Calculated creatinine clearance of \>50 mL/min using Cockcroft Gault equation 5. Total bilirubin ≤ 1.5 x institutional upper limit of normal 6. AST (SGOT) and ALT (SGPT) ≤2.5 x institutional upper limit of normal 7. If Alkaline Phosphatase ≥ 2.5 x institutional upper limit of normal, then AST and ALT must be ≤ 1.5 x institutional upper limit of normal 15. Patients of childbearing age must not be pregnant and must use established contraceptive strategies: 1. Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 2. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgi